Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 28:3:100104.
doi: 10.1016/j.crphar.2022.100104. eCollection 2022.

Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

Pascal Juillerat  1   2 , Maude Martinho Grueber  1   2 , Roseline Ruetsch  2 , Giulia Santi  1 , Marianne Vuillèmoz  2 , Pierre Michetti  2   3
Affiliations
Review

Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

Pascal Juillerat et al. Curr Res Pharmacol Drug Discov. .

Abstract

The number of available biological therapies have doubled over the last 10 years and the arrival of novel molecules (interleukin 23p19 inhibitors) is ongoing alongside the development of small molecules. As a result of this vast landscape of treatment, positioning advanced therapies (according to clinical situation, efficacy and safety) is of paramount importance to providing personalized, appropriate IBD treatment. In this publication the recent available literature is summarized for practical integration into clinical practice including comparative efficacy data, patient and disease demographics. We refer to recent publications and expert opinion in order to facilitate the decision making process of positioning biologicals IBD treatment.

Keywords: Adalimumab; Biological therapy; Infliximab; Monoclonal antibodies; Ustekinumab; Vedolizumab.

PubMed Disclaimer

Conflict of interest statement

Pascal Juillerat ​received consulting fees from AbbVie, Arena Pharma, Amgen, BMS, Ferring, Gilead, Janssen, Lilly, MSD, Pfizer, Pierre Fabre, Roche, Takeda, and Vifor Pharma. Lecture fees from AbbVie, Amgen, Janssen, Pfizer, Takeda, UCB pharma and Vifor Pharma and research grants from Vifor Pharma. ​Maude Martinho Grueber, Roseline Ruetsch, Giulia Santi and Marianne Vullièmoz ​have no conflict of interest to declare. ​Pierre Michetti ​received consulting fees from AstraZeneca, AbbVie, Ferring Pharmaceuticals, Janssen, MSD, Nestlé Health Sciences, Pfizer, Pierre Fabre, Takeda, UCB Pharma, and Vifor Pharma, lecture fees from Ferring Pharmaceuticals, Janssen, Hospira, MSD, Pfizer, Takeda, UCB Pharma, and Vifor Pharma and research grants from iQone.

Figures

Image 1
Graphical abstract
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Allez M., Vermeire S., Mozziconacci N., Michetti P., Laharie D., Louis E., Bigard M.A., Hebuterne X., Treton X., Kohn A., Marteau P., Cortot A., Nichita C., van Assche G., Rutgeerts P., Lemann M., Colombel J.F. The efficacy and safety of a third anti-tnf monoclonal antibody in crohn's disease after failure of two other anti-tnf antibodies. Aliment. Pharmacol. Ther. 2010;31(1):92–101. - PubMed
    1. Alsoud D., Verstockt B., Fiocchi C., Vermeire S. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol. 2021;6(7):589–595. - PubMed
    1. Argollo M., Kotze P.G., Kakkadasam P., D'Haens G. Optimizing biologic therapy in ibd: how essential is therapeutic drug monitoring? Nat. Rev. Gastroenterol. Hepatol. 2020;17(11):702–710. - PubMed
    1. Arias M.T., Vande Casteele N., Vermeire S., de Buck van Overstraeten A., Billiet T., Baert F., Wolthuis A., Van Assche G., Noman M., Hoffman I., D'Hoore A., Gils A., Rutgeerts P., Ferrante M. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin. Gastroenterol. Hepatol. 2015;13(3):531–538. - PubMed
    1. Asscher V.E.R., Biemans V.B.C., Pierik M.J., Dijkstra G., Lowenberg M., van der Marel S., de Boer N.K.H., Bodelier A.G.L., Jansen J.M., West R.L., Haans J.J.L., van Dop W.A., Weersma R.K., Hoentjen F., Maljaars P.W.J., Dutch Initiative on C., Colitis Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study. Aliment. Pharmacol. Ther. 2020;52(8):1366–1376. - PMC - PubMed